| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N63-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 |
| filingDate |
2003-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2005-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2005538742-A |
| titleOfInvention |
Hematopoietic stem cells and methods of treating neovascular diseases of the eye using the cells |
| abstract |
An isolated, mammalian, bone marrow-derived, lineage-negative hematopoietic stem cell population (Lin - HSC) contains endothelial progenitor cells (EPCs) capable of forming retinal blood vessels. At least about 50% of the cells of the isolated Lin HSC population have CD31 and c-kit cell surface markers. Up to about 8% of cells can have a Sca-1 cell marker and up to about 4% of cells can have a Flk-1 / KDR marker. The isolated Lin HSC population of the present invention is useful for treating ocular vascular disease. Also provided is an isolated Lin HSC population transfected with a therapeutically useful gene, which is useful for delivering genes to the eye in cell-based gene therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006166918-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4714580-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4714682-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006525806-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2014030749-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014030749-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150047538-A |
| priorityDate |
2002-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |